Acadia Pharmaceuticals
ACAD
168 hedge funds and large institutions have $2.21B invested in Acadia Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 63 increasing their positions, 53 reducing their positions, and 19 closing their positions.
1,357% more call options, than puts
Call options by funds: $335M | Put options by funds: $23M
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
19% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 53
8% more funds holding
Funds holding: 155 → 168 (+13)
6% more capital invested
Capital invested by funds: $2.08B → $2.21B (+$132M)
45% less funds holding in top 10
Funds holding in top 10: 11 → 6 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$39.6M |
| 2 |
Jennison Associates
New York
|
+$37.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.2M |
| 4 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$24.9M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$24.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$23.3M |
| 2 |
VAM
Visium Asset Management
New York
|
-$22.2M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$15.8M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$12.6M |
| 5 |
CCI
Columbus Circle Investors
|
-$10.8M |
ACAD Hedge Fund Activity: Q1 2014 in Review
168 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2014, worth a combined $2.21B — up 6.4% from $2.08B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ACAD positions and 19 closed out — a net gain of 16 holders — while 63 added to existing stakes and 53 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $39.6M. The largest seller was RA Capital Management, cutting an estimated $23.3M.
- 168 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2014, up from 155 in Q4 2013.
- Funds reported $2.21B of Acadia Pharmaceuticals stock for Q1 2014, up 6.4% quarter-over-quarter.
- 35 funds opened new Acadia Pharmaceuticals positions in Q1 2014 and 19 closed out, a net change of +16 holders.
- The largest Acadia Pharmaceuticals buyer in Q1 2014 was PFM Health Sciences, an estimated $39.6M added.
- The largest Acadia Pharmaceuticals seller in Q1 2014 was RA Capital Management, an estimated $23.3M sold.
Based on aggregated 13F filings for Q1 2014.